source
- Choosing Between CROs and Biotechs: How Company Size Shapes the FitWhile biotechs and contract research organizations each have strengths, the article notes that the right choice depends on a company’s specific situation. Ali Pashazadeh, founder and CEO of Treehi…
- Lilly beats forecasts while Novo Nordisk misses sales and trial targetsEli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…